Prevalence of Subclinical Cardiovascular Disease in Patients with Non-Alcoholic-Fatty Liver Disease: Analysis of the Paracelsus 10.000 Cohort Study.
Journal
Medical principles and practice : international journal of the Kuwait University, Health Science Centre
ISSN: 1423-0151
Titre abrégé: Med Princ Pract
Pays: Switzerland
ID NLM: 8901334
Informations de publication
Date de publication:
07 Sep 2023
07 Sep 2023
Historique:
received:
06
03
2023
accepted:
31
08
2023
medline:
8
9
2023
pubmed:
8
9
2023
entrez:
7
9
2023
Statut:
aheadofprint
Résumé
In patients with non-alcoholic fatty liver disease (NAFLD) cardiovascular diseases are more often the cause of death than the liver disease itself. However, the prevalence of atherosclerotic manifestations in individuals with NAFLD is still uncertain. This study aimed to explore the association between NAFLD and coronary artery calcification (CAC) in a Central European population. A total of 1,743 participants from the Paracelsus 10,000 study were included. The participants underwent CAC scoring and were assessed for fatty liver index (FLI), fibrosing non-alcoholic steatohepatitis Index (FNI) and fibrosis-4 index (FIB-4 score), which are indicators for steatosis and fibrosis. Multivariable logistic regression models were calculated. Results revealed an association between liver steatosis/fibrosis and CAC. A FLI > 60 was associated with higher odds of NAFLD (OR 3.38, 95% CI: 2.61-4.39, p < 0.01) and increased prevalence of CAC-Score >300 compared to FLI <30 (9% vs. 3%, p < 0.01), even after adjusting for traditional cardiometabolic risk factors. While the crude odds ratios of the FIB-4 scores ≥ 1.3 and FNI score were significantly associated with increased odds of CAC, they became non-significant after adjusting for age, sex, and MetS. This study reveals a significant association between NAFLD and CAC. The findings suggest that assessing liver fat and fibrosis could enhance assessment of cardiovascular risk, but further research is needed to determine whether hepatic fat plays an independent role in the development of atherosclerosis and whether targeting liver steatosis can mitigate vascular risk.
Sections du résumé
BACKGROUND
BACKGROUND
In patients with non-alcoholic fatty liver disease (NAFLD) cardiovascular diseases are more often the cause of death than the liver disease itself. However, the prevalence of atherosclerotic manifestations in individuals with NAFLD is still uncertain. This study aimed to explore the association between NAFLD and coronary artery calcification (CAC) in a Central European population.
METHODS
METHODS
A total of 1,743 participants from the Paracelsus 10,000 study were included. The participants underwent CAC scoring and were assessed for fatty liver index (FLI), fibrosing non-alcoholic steatohepatitis Index (FNI) and fibrosis-4 index (FIB-4 score), which are indicators for steatosis and fibrosis. Multivariable logistic regression models were calculated.
RESULTS
RESULTS
Results revealed an association between liver steatosis/fibrosis and CAC. A FLI > 60 was associated with higher odds of NAFLD (OR 3.38, 95% CI: 2.61-4.39, p < 0.01) and increased prevalence of CAC-Score >300 compared to FLI <30 (9% vs. 3%, p < 0.01), even after adjusting for traditional cardiometabolic risk factors. While the crude odds ratios of the FIB-4 scores ≥ 1.3 and FNI score were significantly associated with increased odds of CAC, they became non-significant after adjusting for age, sex, and MetS.
CONCLUSION
CONCLUSIONS
This study reveals a significant association between NAFLD and CAC. The findings suggest that assessing liver fat and fibrosis could enhance assessment of cardiovascular risk, but further research is needed to determine whether hepatic fat plays an independent role in the development of atherosclerosis and whether targeting liver steatosis can mitigate vascular risk.
Identifiants
pubmed: 37678174
pii: 000533909
doi: 10.1159/000533909
pmc: PMC10659702
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
The Author(s). Published by S. Karger AG, Basel.
Références
Arterioscler Thromb Vasc Biol. 2022 Jun;42(6):e168-e185
pubmed: 35418240
J Hepatol. 2016 Jun;64(6):1388-402
pubmed: 27062661
Semin Thromb Hemost. 2009 Apr;35(3):277-87
pubmed: 19452403
Metabolism. 2020 Oct;111S:154170
pubmed: 32006558
J Am Coll Cardiol. 2005 Sep 6;46(5):807-14
pubmed: 16139129
J Am Coll Cardiol. 1990 Mar 15;15(4):827-32
pubmed: 2407762
Diagnostics (Basel). 2021 Jan 09;11(1):
pubmed: 33435415
Sci Rep. 2020 Oct 27;10(1):18323
pubmed: 33110139
Clin Gastroenterol Hepatol. 2023 Jun;21(6):1523-1532.e1
pubmed: 35421583
J Gastroenterol Hepatol. 2018 Jan;33(1):70-85
pubmed: 28670712
Eur Heart J. 2012 Jul;33(13):1635-701
pubmed: 22555213
J Gastroenterol Hepatol. 2018 Jan;33(1):86-98
pubmed: 28692197
Eur Heart J. 2021 Jul 1;42(25):2439-2454
pubmed: 34120177
Hepatology. 2007 Jul;46(1):32-6
pubmed: 17567829
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
J Hepatol. 2020 Jul;73(1):202-209
pubmed: 32278004
JGH Open. 2021 Feb 19;5(3):390-395
pubmed: 33732887
Circulation. 2002 Aug 6;106(6):653-8
pubmed: 12163423
Trials. 2015 Dec 05;16:554
pubmed: 26637993
Circulation. 2019 Sep 10;140(11):e596-e646
pubmed: 30879355
BMC Gastroenterol. 2006 Nov 02;6:33
pubmed: 17081293
J Hepatol. 2015 Jul;63(1):237-64
pubmed: 25911335
Circulation. 2005 Oct 25;112(17):2735-52
pubmed: 16157765